Alphabiome

Executive Summary

Alphabiome is an Israeli AI-driven biotech company that leverages unsupervised machine learning to decode reference-free microbial DNA, enabling the discovery of genetic biomarkers that predict drug efficacy. Founded in 2020 and based in Tel Aviv, the company addresses a critical gap in precision medicine by transforming untapped microbiome data into actionable insights for drug development. Its platform has the potential to improve clinical trial success rates and enable personalized therapeutics. With $8 million in funding and a platform-stage focus, Alphabiome is positioned to validate its technology through partnerships and further capital raises. The company's unique approach to biomarker discovery could unlock significant value in the rapidly growing microbiome therapeutics market, though it remains early-stage with limited public data.

Upcoming Catalysts (preview)

• Q2 2027Pharma partnership for biomarker validation40% success
• Q4 2026Series A funding round closing60% success
• Q1 2027Publication of preclinical proof-of-concept data70% success